* INJ currently trading at $13.31 (+7.60% in 24h) * INJ RSI sits in neutral territory at 50.34, suggesting balanced momentum * Cboe’s staked Injective ETF filing and EVM compatibility upgrade drive long-term optimism
The INJ price recovery comes after a period of consolidation that saw the token decline from recent highs. Over the past 24 hours, Injective has gained 7.60%, bouncing from the $12.35 low to reach $13.31, indicating renewed buying interest at key Injective support levels.
Recent market dynamics show a classic pattern of initial enthusiasm followed by profit-taking. Despite the Cboe filing for the first staked Injective ETF in the United States on July 28th and the successful launch of the Ethernia Upgrade with EVM compatibility on July 31st, the INJ price experienced an 8.77% decline to $13.01 on August 1st as traders secured profits from earlier gains.
The consolidation phase continued into August 3rd, with INJ trading at $12.39 after a 2.29% decline, testing crucial support zones. However, today’s 7.6% recovery suggests that the selling pressure may be easing, with the market beginning to price in the long-term implications of these fundamental developments.
The Ethernia Upgrade represents a significant technical milestone for Injective, introducing Ethereum Virtual Machine compatibility that could attract more developers and increase network activity. Meanwhile, the Cboe ETF filing signals growing institutional interest in INJ, potentially opening new avenues for mainstream investment exposure.
Injective technical analysis reveals a market in transition, with momentum indicators suggesting near-term uncertainty despite the overall bullish trend. The INJ RSI currently reads 50.34, placing it squarely in neutral territory and indicating neither overbought nor oversold conditions.
Injective’s MACD presents a nuanced picture, with the main line at 0.1395 above the signal line at 0.4091, but the histogram showing -0.2696, suggesting bearish momentum in the short term. This divergence often occurs during consolidation phases when the market digests recent moves.
The moving average structure provides more clarity on the underlying trend. INJ trades above the 50-day SMA at $12.30 and the 200-day SMA at $12.39, confirming the longer-term bullish bias. However, the current INJ price of $13.31 remains below the 20-day SMA at $13.95, indicating short-term resistance overhead.
Injective’s Bollinger Bands show the token positioned at 0.3161 between the bands, with the upper band at $15.71 and lower band at $12.20. This positioning suggests room for movement in either direction, with the middle band at $13.95 serving as a key resistance level.
The daily ATR of $1.13 indicates moderate volatility, providing opportunities for active traders while suggesting that significant moves require strong catalysts.
Based on Binance spot market data, several critical INJ price levels emerge for traders to monitor. The immediate resistance sits at $16.35, which also represents the strong resistance level. A break above this zone could signal a resumption of the broader uptrend and potentially target the next significant level.
On the downside, Injective support levels are well-defined. The immediate support at $11.91 represents the first line of defense, closely aligned with the recent consolidation lows. Should this level fail, the strong support at $8.95 would become the next critical zone to watch.
The pivot point at $13.05 provides additional context, sitting just below the current INJ price and serving as a potential support level in case of renewed selling pressure. The proximity of the current price to this pivot suggests the market remains in a decisive phase.
Traders should note that INJ has shown resilience above the $12.20 Bollinger Band lower boundary, indicating that buyers are stepping in at key technical levels. The 24-hour trading range of $13.48 to $12.35 provides immediate boundaries for short-term trading strategies.
The current setup presents different opportunities depending on trading timeframes and risk tolerance. For swing traders, the recent consolidation has potentially created an attractive entry point, especially given the fundamental catalysts of the ETF filing and EVM upgrade.
Conservative traders might wait for a clear break above the $13.95 resistance (20-day SMA) before entering positions, using the $11.91 support as a stop-loss level. This approach offers a risk-reward ratio of approximately 1:2 if targeting the $16.35 resistance.
More aggressive traders could consider the current levels attractive, given the neutral INJ RSI and the fact that the token has held above key moving averages. However, position sizing should account for the potential for further consolidation, with the $12.35 recent low serving as a key reference point.
Day traders should monitor the $13.95 level closely, as a break above could trigger momentum buying toward the upper Bollinger Band at $15.71. Conversely, failure to hold above $13.05 might suggest further downside testing.
The fundamental backdrop remains supportive, with the Cboe ETF filing representing a significant institutional validation of Injective’s potential, while the EVM compatibility could drive increased developer activity and network growth.
The INJ price action over the next 24-48 hours will likely depend on whether buyers can sustain momentum above the current $13.31 level and challenge the $13.95 resistance. The combination of recent fundamental developments and technical consolidation has created a setup where a decisive move in either direction appears increasingly likely. Traders should monitor the $13.05 pivot point and $11.91 support for signs of strength or weakness, while keeping the broader bullish trend context in mind.
